Tobacco Use CessationNCT06219551
Smoking Cessation Support for Patients With Rheumatologic Diseases Via WhatsApp
A study testing Mobile messages via What's App in people with Tobacco Use Cessation, run by Recep Tayyip Erdogan University Training and Research Hospital at 1 site in Turkey (Türkiye).
Trial summary
Smoking cessation support for patients with rheumatologist diseases is an underestimated issue. In the previous prospective cohort study the investigators determined that with the brief cessation interventions 63.5% of smokers with rheumatologic diseases were willing to quit and the rest 36.4% were not willing. Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Tobacco Use Cessation
- What is being tested?
- Mobile messages via What's App
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 220 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 10 Nov 2023to 30 Jun 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients applying to the rheumatology outpatient clinic
- Those aged 18 and over
- Those who are active smokers
- Those diagnosed with inflammatory rheumatic disease
- Those who gave informed written consent to participate in the study
Who cannot join
- Those with active psychiatric disease diagnoses such as psychosis, major depression, schizophrenia among their current diagnoses
- Those with cognitive dysfunction
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site
Recep Tayyip Erdoğan University, Training and Research Hospital
Rize
About this study
Official title: The Effect of Supporting Routine Smoking Cessation Interventions With Whatsapp-mediated Motivational Information on Smoking Cessation Success in Active Smokers With Inflammatory Rheumatic Diseases: A Randomized Controlled Study
Smoking cessation support for patients with rheumatologist diseases is an underestimated issue. In the previous prospective cohort study the investigators determined that with the brief cessation interventions 63.5% of smokers with rheumatologic diseases were willing to quit and the rest 36.4% were not willing. Among the willing group the highest quit rate was detected in the group that admitted to smoking cessation clinic. Therefore to increase the willingness to quit as well as to increase the Access to evidence based tobacco cessation support using new comminication technologies can be relevant. Investigators' aim in this study is to examine the effect of including WhatsApp in the routine smoking cessation practices on the quitting success of active smokers with rheumatic diseases who apply to the Rheumatology outpatient clinic.
Read the detailed description
In this randomized controlled study, the sample will be randomly divided to 2 arms. In one arm, usual care arm, smoker patients with rheumatologist diseases will be implemented brief smoking cessation interventions and referred to quit lines or smoking cessation services and also directly contacted to get an appointment from the cessation clinic. In the other arm, the intervention arm, smoker patients with rheumatologist diseases will be implemented brief tobacco cessation interventions and directly contacted to get an appointment from cessation clinic and will be send periodically motivational and informative text messages regarding tobacco cessation via WhatsApp.
Primary outcome measures will be the quit rate of both arms at 3rd, 6th and 12th month.
Secondary outcomes will be access to evidence based smoking cessation support, admission rate of smoking cessation clinic and treatment use duration of cessation medications.
- Conditions
- Tobacco Use Cessation
- Being tested
- Mobile messages via What's App
- Keywords
- tobacco cessation, rheumatologic diseases, smoking cessation support
- Medical subject headings
- Tobacco Use Cessation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Mobile messages via What's AppOther
The information article that was prepared by taking the opinions of academics experienced in adult education, and were prepared as a video by the primary Rheumatologist who performs the randomization and will be shared in the Whatsapp group as information. Additionally, information will be provided once a week regarding the appointment date of the smoking cessation clinic.
| Study group | Role | What they receive |
|---|---|---|
| Usual care | Active comparator | Usual care arm, smoker patients with rheumatologist diseases will be implemented brief smoking cessation interventions and referred to quit lines or smoking cessation services and also directly contacted to get an appointment from the cessation clinic. Receives: Other: Mobile messages via What's App |
| Intervention | Experimental | The intervention arm, smoker patients with rheumatologist diseases will be implemented brief tobacco cessation interventions and directly contacted to get an appointment from cessation clinic and will be send periodically motivational and informative text messages regarding tobacco cessation via WhatsApp. Receives: Other: Mobile messages via What's App |
What is being measured
The primary outcome is the main question the study is designed to answer.
Rate of participants with successful quit attempt
Successful quitter: sustained abstinence since the target quit date will be asked and validated by exhaled breath carbon monoxide measure.
Measured: 3-6 and 12 months after the randomization
Secondary outcomes (1)
Access to evidence based cessation support
Admitters to cessation clinics
Measured: Within one year after the randomization
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Jan 2024
- Study start10 Nov 2023
- Primary completion1 May 2025
- Study completion30 Jun 2025
Why it stopped: Enough participants included to the study.
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Tobacco Use CessationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Randomized controlled, paralel arm, prospective cohort
- Masking
- None (open label)
- Enrolment
- 220 participants (actual)
Sponsor and investigators
- Lead sponsor
- Recep Tayyip Erdogan University Training and Research Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Dilek KARADOĞAN, Recep Tayyip Erdogan University Training and Research Hospital
- Investigators
- Osman Cüre, M.D, Principal investigator, Recep Tayyip Erdoğan University Department of Rheumatology
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06219551
- Sponsor's protocol ID
- SCRW
- Status last verified
- Jul 2025
- First submitted
- 13 Dec 2023
- Last updated
- 25 Jul 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Cheung YT, Chan CH, Lai CK, Chan WF, Wang MP, Li HC, Chan SS, Lam TH. Using WhatsApp and Facebook Online Social Groups for Smoking Relapse Prevention for Recent Quitters: A Pilot Pragmatic Cluster Randomized Controlled Trial. J Med Internet Res. 2015 Oct 22;17(10):e238. doi: 10.2196/jmir.4829.
PubMed 26494159
Study at a glance
From the registry record, last updated by the sponsor on 25 Jul 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effect of Supporting Routine Smoking Cessation Interventions With Whatsapp-mediated Motivational Information on Smoking Cessation Success in Active Smokers With Inflammatory Rheumatic Diseases: A Randomized Controlled Study
- ClinicalTrials.gov ID
- NCT06219551
- Acronym / sponsor ID
- SCRW
- Conditions
- Tobacco Use Cessation
- Keywords
- tobacco cessation, rheumatologic diseases, smoking cessation support
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: Enough participants included to the study.
- Enrolment
- 220 participants (actual)
- Lead sponsor
- Recep Tayyip Erdogan University Training and Research HospitalUniversity, hospital or other
- Study start
- 10 Nov 2023 (actual)
- Primary completion
- 1 May 2025 (actual)
- Study completion
- 30 Jun 2025 (actual)
- First posted
- 23 Jan 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Smoking cessation support for patients with rheumatologist diseases is an underestimated issue. In the previous prospective cohort study the investigators determined that with the brief cessation interventions 63.5% of smokers with rheumatologic diseases were willing to quit and the rest 36.4% were not willing. Among the willing group the highest quit rate was detected in the group that admitted to smoking cessation clinic. Therefore to increase the willingness to quit as well as to increase the Access to evidence based tobacco cessation support using new comminication technologies can be relevant. Investigators' aim in this study is to examine the effect of including WhatsApp in the routine smoking cessation practices on the quitting success of active smokers with rheumatic diseases who apply to the Rheumatology outpatient clinic.
Detailed description
In this randomized controlled study, the sample will be randomly divided to 2 arms. In one arm, usual care arm, smoker patients with rheumatologist diseases will be implemented brief smoking cessation interventions and referred to quit lines or smoking cessation services and also directly contacted to get an appointment from the cessation clinic. In the other arm, the intervention arm, smoker patients with rheumatologist diseases will be implemented brief tobacco cessation interventions and directly contacted to get an appointment from cessation clinic and will be send periodically motivational and informative text messages regarding tobacco cessation via WhatsApp.
Primary outcome measures will be the quit rate of both arms at 3rd, 6th and 12th month.
Secondary outcomes will be access to evidence based smoking cessation support, admission rate of smoking cessation clinic and treatment use duration of cessation medications.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Randomized controlled, paralel arm, prospective cohort
| Arm | Type | Receives |
|---|---|---|
| Usual care | Active comparator | Other: Mobile messages via What's AppUsual care arm, smoker patients with rheumatologist diseases will be implemented brief smoking cessation interventions and referred to quit lines or smoking cessation services and also directly contacted to get an appointment from the cessation clinic. |
| Intervention | Experimental | Other: Mobile messages via What's AppThe intervention arm, smoker patients with rheumatologist diseases will be implemented brief tobacco cessation interventions and directly contacted to get an appointment from cessation clinic and will be send periodically motivational and informative text messages regarding tobacco cessation via WhatsApp. |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Patients applying to the rheumatology outpatient clinic
- Those aged 18 and over
- Those who are active smokers
- Those diagnosed with inflammatory rheumatic disease
- Those who gave informed written consent to participate in the study
Key exclusion criteria (2 listed)
- Those with active psychiatric disease diagnoses such as psychosis, major depression, schizophrenia among their current diagnoses
- Those with cognitive dysfunction
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Mobile messages via What's AppThe information article that was prepared by taking the opinions of academics experienced in adult education, and were prepared as a video by the primary Rheumatologist who performs the randomization and will be shared in the Whatsapp group as information. Additionally, information will be provided once a week regarding the appointment date of the smoking cessation clinic. | Other | Intervention, Usual care |
Primary outcome
Rate of participants with successful quit attempt
Time frame: 3-6 and 12 months after the randomization
Successful quitter: sustained abstinence since the target quit date will be asked and validated by exhaled breath carbon monoxide measure.
1 secondary outcome
Access to evidence based cessation support
Time frame: Within one year after the randomization
Results and safety
The study was stopped early (reason given: Enough participants included to the study.). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Jul 2025.
- Results publication: PubMed 26494159Cheung YT, Chan CH, Lai CK, Chan WF, Wang MP, Li HC, Chan SS, Lam TH. Using WhatsApp and Facebook Online Social Groups for Smoking Relapse Prevention for Recent Quitters: A Pilot Pragmatic Cluster Randomized Controlled Trial. J Med Internet Res. 2015 Oct 22;17(10):e238. doi: 10.2196/jmir.4829.
- An example of a comprehensive approach to increase the access to evidence-based tobacco cessation support for smokers with rheumatic diseasesLink provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for Tobacco Use Cessation
Not yet recruitingObservational study
PROMETHEE: A Shared Interregional Tele-Tobacco Cessation Platform Embedded Within the IMPULSION Lung Cancer Screening Program
Smoking Cessation, Lung Cancer Screening
Not yet recruiting
Impacto 2.0: Mobile Smoking Cessation Across Texas
Cigarette Smoking, Smoking Cessation
Active, not recruiting
Vaping Cessation Using the Ottawa Model for Smoking Cessation Among E-Cigarette Users
Tobacco Smoking, Vaping
Recruiting
Young Adult Tobacco/Nicotine and Cannabis Co-use
Tobacco Use Disorder, Nicotine Dependence
Recruiting
Social Media Support Groups for Adolescent Vaping Cessation
Vaping, Vaping Cessation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Osman Cüre, M.D principal investigator
Recep Tayyip Erdoğan University Department of Rheumatology
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Mobile messages via What's App in people with Tobacco Use Cessation, run by Recep Tayyip Erdogan University Training and Research Hospital at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 25 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was stopped early (reason given: Enough participants included to the study.). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Rate of participants with successful quit attempt (time frame: 3-6 and 12 months after the randomization). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06219551, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Jul 2025.